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Abstract: Interleukin-1 (IL-1) is a critical neuroinflammatory mediator in the central nervous 
system (CNS). In this study, we investigated the effect of IL-1 on inducing inflammation-
related gene expression in three astrocyte, two microglial, and one brain endothelial cell line. 
Interleukin-1 beta (IL-1β) is found to be produced by the two microglial cell lines   constitutively, 
but these cells do not respond to IL-1β stimulation. The three astrocyte cell lines responded 
to IL-1β stimulation by expressing MCP-1, CXCL-1, and VCAM-1, but different subtypes of 
astrocytes exhibited different expression profiles after IL-1β stimulation. The brain e  ndothelial 
cells showed strongest response to IL-1β by producing MCP-1, CXCL-1, VCAM-1, ICAM-1, 
IL-6, and COX-2 mRNA. The induction of endothelial COX-2 mRNA is shown to be   mediated 
by p38 MAPK pathway, whereas the induction of other genes is mediated by the NF-κB p  athway. 
These results demonstrate that IL-1 exerts distinct cell type-specific action in CNS cells and 
s  uggest that IL-1-mediated neuroinflammation is the result of the summation of multiple 
responses from different cell types in the CNS to IL-1.
Keywords: astrocyte, microglia, endothelial cells, signal transduction pathways, gene 
expression
Introduction
Interleukin-1 (IL-1) is involved in multiple functions in the central nervous system 
(CNS). In neuroimmune communication, IL-1 induces fever, increased slow wave 
sleep, increased hypothalamic-pituitary-adrenal (HPA) activation, and sickness 
behaviors.1 During brain injury, IL-1 modulates neural inflammation to exacerbate2 
or reduce secondary tissue damage, depending on specific conditions.3 In Alzheimer’s 
disease, IL-1 was implicated as a critical inflammatory cytokine that could contribute 
to the progression of this disease.4 Current literature suggests that IL-1 is involved in 
n  umerous physiological and pathological processes in the CNS.
The diverse activities of IL-1 in the CNS have been associated with the different 
cell types that IL-1 might act on. For example, IL-1-induced sickness behavior has 
been associated with IL-1’s action on brain endothelial cells;5 IL-1-mediated changes in 
brain tissue injury and recovery have been associated with IL-1’s action on astrocytes;6 
and IL-1-induced changes in brain cytokine levels have been associated with IL-1’s 
action on microglia.7 Whether IL-1 induces distinct effects from these different CNS 
cell types has not been clarified.
In vivo, when IL-1 is injected directly into the cerebral ventricles, many dif  ferent 
cell types are activated, including neurons, astrocytes, microglia, and endothelial 
cells.8 Activation of these cell types causes discrete patterns of gene expression in Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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  different cell types: eg, c-fos in paraventricular nucleus 
(PVN)   neurons, glial fibrillary acidic protein (GFAP) in 
astrocytes, IL-1 in microglia, and COX-2 in endothelial 
cells. It is not clear, however, which cells are activated by 
the direct action of IL-1 on the receptors of IL-1 on the cell 
membrane and which cells are activated, not by IL-1 directly, 
but indirectly by other signaling molecules induced by IL-1 
from a different cell type.
Previous studies have attempted to isolate the direct 
action of IL-1 on a specific CNS cell type by examining the 
effects of IL-1, in vitro, in primary cultures.9–11 These primary 
cultures were typically generated from neonatal brains; the 
results generated from these cultures may not reflect IL-1’s 
effect on adult CNS cells.12 More importantly, cells in the 
primary culture are generally not pure, rendering complete 
exclusion of an observed effect from contaminating cell 
types difficult.
In this study, we tested patterns of selected gene 
e  xpression in several CNS cell lines representing different 
cell types of the CNS. In addition, we examined the signal 
transduction pathways mediating IL-1-induced effects in 
these cell types.
Materials and methods
Cell culture
The murine astrocyte cell lines (C8-D1A, C8-D30, and C8-S), 
murine brain endothelial cell line (bEnd.3), and murine 
peripheral endothelial cell line (SVEC4-10) were cultured in 
Dulbecco’s modified eagle medium (DMEM) (supplemented 
with 10% fetal bovine serum [FBS], 100 units/mL penicillin G, 
100 µg/mL streptomycin). The murine   microglial cell lines 
(EOC2 and EOC20) were cultured in the growth medium 
(DMEM, 70%; LADMAC [mouse bone m  arrow, producing 
colony stimulating factor-1]-conditioned media, 20%; and 
FBS, 10%). Cultures were maintained at 37°C with 95% 
humidity and 5% CO2. Cells were used at approximately 
90% confluency.
experimental manipulation
Cells were seeded in 6-well plates with 2 × 106 cells/well. 
Recombinant mouse interleukin-1 beta (IL-1β) (1 ng/mL, 
R&D Systems®, Minneapolis, MN) was used to stimulate the 
astrocytes and brain endothelial cells for 2, 4, or 16 hours. 
Culture medium (MC) was used as control. In signal trans-
duction blockade experiments, SP600125 (JNK inhibitor II, 
40 µM, Calbiochem®, EMD Chemicals Inc, Gibbstown, 
NJ), PD98059 (MEK1 inhibitor, 20 µM, Calbiochem®), 
SB203580 (p38 MAPK inhibitor, 20 µM, Calbiochem®), 
or BAY11-7082 (NF-κB pathway inhibitor 5 µM, Biomol®, 
Enzo Life Sciences, Plymouth Meeting, PA) was first 
d  issolved in dimethyl sulfoxide (DMSO) and then added to 
the culture medium 1 hour before IL-1β stimulation. Cells 
were harvested 2 hours after IL-1β stimulation.
RNA isolation and cDNA preparation
Cells were harvested and mRNA was isolated (Qiagen 
RNeasy® Mini Kit, Valencia, CA) from both IL-1β- treated 
cells and control cells. The RNase-Free DNase Set (  Qiagen, 
Valencia, CA) was used to digest DNA during RNA 
p  urification. To generate cDNA, 1 µg of RNA was mixed 
with 300 ng of random primer (Invitrogen™, Carlsbad, CA) 
and 1 µL of 10 mM dNTPs for each sample. The mixture was 
incubated at 70°C for 5 minutes and then chilled on ice. Then, 
the   mixture was incubated with 2 µL reverse   transcription 
buffer and 1µL M-MuLV reverse transcriptase (New E  ngland 
B  iolabs®, I  pswich, MA) at 37°C for 1 hour. Finally, the 
r  esulting cDNAs were heated to 95°C for 5 minutes to inac-
tivate the enzyme and were stored at -20°C until use.
Real-time polymerase chain reaction
Polymerase chain reaction (PCR) analyses were performed 
to detect the expression of iNOS, Cox-2, TNF-α, IL-6, 
IL-1β, IL-1R1, MCP-1, CXCL-1, VCAM-1, ICAM-1, and 
G3PDH (as an internal control). PCR primers used in this 
study are listed in Table 1 (TNF-α primers were obtained 
from Applied Biosystem TaqMan® gene expression assay, 
Carlsbad, CA). The expression of IL-1 receptor, type I 
(IL-1R1) gene was detected by SYBR® green PCR system 
(Applied Biosystem, Carlsbad, CA), while the expression 
of all other genes was detected by the iCycler iQ real-time 
system (Bio-Rad, Hercules, CA). Real-time PCR results 
were expressed as relative levels of RNA over that of the 
G3PDH. The detection limit of real-time PCR was set 
by the threshold cycle number of a PCR, which detects a 
single copy of a given sequence. A sample was deemed 
undetectable if the threshold PCR cycle number was over 
the detection limit.
eLISA
ELISA kits for MCP-1, VCAM-1, COX-2 (R&D Systems®, 
Minneapolis, MN, catalog number: MEJ00, MVC00, and 
KCB4198, respectively), and IL-6 (BD Biosciences, San 
Diego, CA, catalog number 555240) were used. Protein 
levels of MCP-1, VCAM-1 and IL-6 were measured in cell 
s  upernatant according to the manufacturer’s i  nstructions. 
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Table 1 pCR primers for real-time pCR measurement of target genes
Name Forward Reverse Probe
IL-1R1 5′-GTCCCTGACTTCAAGAATTACC 5′-CTCCAAGACCTCAGGCAACAG NA
CXCL-1 5′-CTGCACCCAAACCGAAGTC 5′-AGCTTCAGGGTCAAGGCAAG 5′-CACTCAAGAATGGTCGCGAGGC
MCP-1 5′-TTGGCTCAGCCAGATGCA 5′-CCTACTCATTGGGATCATCTTGC 5′-AACGCCCCACTCACCTGCTGCTAC
ICAM-1 5′-CACAGAACTGGATCTCAG 5′-GAGCTTTGGGATGGTAGCTG 5′-TGGCATTGTTCTCTAATGTCTCCGAGGC
VCAM-1 5′-CGATTGCTCAAATCGGTGAC 5′-GTCTATCTGGGTTCTCCATG 5′-TCCATGGCCCTCACTTGCAGCA
COX-2 5′-CAGCCAGGCAGCAAATCC 5′-TCAAATCCTGTGCTCATACATT 5′-TGCTGTTCCAATCCATGTCAAAAC
IL-1β 5′-GGCCTCAAAGGAAAGAATCTATACC 5′-GTATTGCTTGGGATCCACACTCT 5′-ATGAAAGACGGCACACCCACCCTG
IL-6 5′-TATGAAGTTCCTCTCTGCAAGAGA 5′-TAGGGAAGGCCGTGGTT 5′-CCAGCATCAGTCCCAAGAAGGCAA
iNOS 5′-CAGCTGGGCTGTACAACCTT 5′-TGAATGTGATGTTTGCTTCGG 5′-CGGGCAGCCTGTGAGACCTTTGAT
G3pDh 5′-GGCAAATTCAACGGCACAGT 5′-GGGTCTCGCTCCTGGAAGAT 5′-AAGGCCGAGAATGGGAAGCTTGTCATC
Markers IL-1β
Astrocytes Brain endo.
C8-D1A C8-S C8-D30 bEnd.3
CXCL-1 + + + + + + + + + + +
MCP-1 + + + + + + + + +
ICAM-1 - - - + + +
VCAM-1 + + - + + + + +
COX-2 + - - + + +
IL-6 - - - + + +
  IL-1β/BAY11-7082
CXCL-1 + - + +
MCP-1 + - + +
ICAM-1 - - - -
VCAM-1 + - - +
COX-2 - - - + + +
IL-6 - - - -
  IL-1β/SB203580
CXCL-1 + + + + + + + + + + +
MCP-1 + + + + + + + + +
ICAM-1 - - - + + +
VCAM-1 + + - + + + + +
COX-2 + - - -
IL-6 - - - + + +
Note: IL-1R1 is measured by the SYBR green method, which does not require a probe.
Abbreviation: pCR, polymerase chain reaction.
bEnd.3 cells were stimulated by 1 ng/mL of IL-1β for 
4 hours. Culture medium was used as control. Cell 
s  upernatant samples were centrifuged to remove particulates 
and were aliquoted and stored at -20°C before use. Protein 
levels were calculated using standard curves generated from 
reference proteins provided in the ELISA kits.
COX-2, an intracellular protein, was measured by a cell-
based ELISA. A total of 20,000 C8-S, C8-D1A, C8-D30, 
or bEnd.3 cells were seeded into each well of the 96-well 
microplate overnight. Cells were treated with 1 ng/mL of 
IL-1β for 4 hours or with control medium. Then, the cells 
were fixed in 4% formaldehyde, quenched with a wash buffer 
containing 0.6% H2O2 and blocked with a blocking buffer 
containing 10% FBS (these buffers were provided in the kit). 
Cellular COX-2 and GAPDH were detected by a mouse 
anti-COX-2 and a rabbit anti-GAPDH. The anti-COX-2 
antibody was labeled by a secondary antibody conjugated 
with horse radish peroxidase (HRP) and visualized by a 
fluorescence substrate (F1, detectable at 600 nm) and the 
anti-GAPDH antibody was labeled by a secondary antibody 
conjugated with alkaline phosphatase (AP) and visualized by 
a different fluorescence substrate (F2,   detectable at 450 nm). 
Control wells, with no primary antibody added, were 
included to establish background fluorescence. Background 
fl  uorescence was subtracted from the fluorescence in sample 
wells. COX-2 protein levels were calculated by dividing Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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the COX-2-detecting fluorescence at 600 nm in each well 
by the GAPDH-detecting fluorescence at 450 nm in each 
well to obtain relative fluorescence unit (RFU).
Statistical analysis
All the data are presented as mean ± standard error of 
the mean (SEM). Variations in mRNA expression levels 
were evaluated by one-way analysis of variance (ANOVA) 
f  ollowed by post-hoc analysis (Tukey test). All tests were 
considered significant if P , 0.05.
Results
Figure 1 shows that IL-1R1 was detectable in all three 
a  strocyte cell lines and the brain endothelial cell line; it was 
not detected in the two microglial cell lines (data not shown). 
We also detected IL-1R1 in the peripheral endothelial cell 
line, SVEC4-10, which is known to express IL-1R1, to verify 
our analysis (Figure 1). In the astrocyte lines, IL-1β induced 
increased expression of MCP-1, CXCL-1, and VCAM-1 
(Figure 2). Increased expression of MCP-1 was found in 
all three astrocyte lines, with the highest induction levels 
occurring at 2 hours after the IL-1β stimulation and the level 
of induced MCP-1 declining precipitously at 4 and 16 hours 
post-IL-1β stimulation. The strongest   induction occurred in 
the C8-D30 line and the weakest in the C8-S line. S  imilarly, 
CXCL-1 was induced by IL-1β in all three astrocyte lines; the 
strongest induction occurred again in the C8-D30 line, but 
the weakest induction was found in C8-D1A cells. VCAM-1 
was not induced in C8-S cells, but in both C8-D1A and 
C8-D30 cells, with the stronger i  nduction in C8-D1A cells. 
IL-1β did not induce the e  xpression of ICAM-1, COX-2, 
iNOS, TNFα, IL-1β, and IL-6 in these astrocyte lines 
(data not shown).
IL-1β-induced gene expression in the brain endothelial 
cell line is shown in Figure 3. The endothelial genes that 
were induced by IL-1β include MCP-1, ICAM-1, CXCL-1, 
VCAM-1, IL-6, and COX-2, whereas the expression of 
iNOS, TNFα, and IL-1β was not induced by IL-1β (data not 
shown). Again, peak induction levels were seen at 2 hours 
post-IL-1β stimulation. Whereas MCP-1, ICAM-1, CXCL-1, 
VCAM-1, and COX-2 mRNA expression gradually declined 
thereafter, the IL-6 expression abruptly returned to the basal 
level at 4 hours post-IL-1β stimulation.
Previous studies have shown that the microglial cell is 
a major producer of inflammatory mediators. In addition, 
cells with very low expression of IL-1R1 were known to 
respond to IL-1β stimulation.13 Therefore, we examined 
IL-1β-induced gene expression in the two microglial cell 
lines, although IL-1R1 mRNA was not detected in either line. 
Figure 4 shows that TNFα, IL-1β, MCP-1, and iNOS were 
constitutively expressed in the EOC2 cells (Figures 4A–D). 
After IL-1β stimulation, the expression of these genes was not 
changed at 2, 4, and 16 hours post stimulation. Similarly, in 
EOC20 cells, TNFα, IL-1β, and MCP-1 were constitutively 
expressed and their expression was not altered after the IL-1β 
stimulation (Figures 4A–C).
Next, we used specific inhibitors of signal transduction to 
determine the signaling pathways that mediate IL-1β-induced 
gene expression. NF-κB pathway inhibitor (BAY11-7082), 
JNK pathway inhibitor (JNK inhibitor II), ERK pathway 
inhibitor (PD98059), or p38 MAPK inhibitor (SB203580) 
was used. Because the highest gene expression occurred 
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Figure 2 Time course of gene expression after IL-1β stimulation in the three 
astrocyte cell lines.
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the G3pDh levels in the same sample) are presented. *Indicates significant increase 
of an mRNA after IL-1β stimulation over the control mRNA values (P , 0.05).
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at 2 hours after IL-1β stimulation, we pretreated cells with 
an inhibitor for 1 hour and stimulated cells with IL-1β for 
2 hours. Figure 5 shows that in astrocyte lines, the induced 
expression of MCP-1, VCAM-1, and CXCL-1 can all be 
completely inhibited by the NF-κB inhibitor, BAY11-7082. 
Other inhibitors did not alter IL-1β-induced gene expres-
sion in these astrocyte lines. Figure 6 shows that in the brain 
endothelial cell line, pretreatment of BAY11-7082 abrogated 
the induction of MCP-1, CXCL-1, VCAM-1, ICAM-1, and 
IL-6. Other inhibitors did not alter IL-1β-induced expression 
of these genes (data not shown). In contrast, IL-1β-induced 
COX-2 expression was not inhibited by BAY-11-7082, but 
by SB203580.
To examine whether the distinct induction patterns 
observed at the mRNA level are mirrored at the protein 
level, we measured IL-1β-induced MCP-1, VCAM-1, IL-6, 
and COX-2 protein levels in the three astrocyte cell lines and 
brain endothelial cell line (Figure 7). MCP-1 protein was 
induced in all four cell lines, with the lowest induction in the 
C8-S cells (Figure 7A). VCAM-1 was induced in C8-D1A, 
C8-D30, and brain endothelial bEnD.3 cells, but not in C8-S 
cells (Figure 7B). The strongest induction occurred in the 
bEnD.3 cells withVCAM-1 in bEnD.3 more than seven times 
higher than those in the other cells. Whereas IL-6 was not 
induced in C8-S and C8-D1A cells, it was dramatically 
induced in both C8-D30 and bEnD.3 cells (Figure 7C). 
COX-2 was not induced in all three astrocytes, but was 
induced in the brain endothelial cells (Figure 7D).
Discussion
IL-1R1 is expressed at very different levels in the tested brain 
endothelial, astrocyte, and microglial cell lines. The highest 
expression of IL-1R1 is found in brain endothelial cells 
(  Figure 1). This is consistent with previous s  tudies that 
showed brain endothelial cell as the major cell type that 
c  arries CNS IL-1R1.14–16 In addition, endothelial IL-1R1 has 
been shown to mediate fever, brain endothelial COX-2 
expression, and CNS leukocyte infiltration induced by 
intracerebral IL-1β injection.5 In addition, our real-time PCR 
assay also detected IL-1R1 in a peripheral endothelial cell 
line, SVEC4-10, confirming the ability of the assay to detect 
known IL-1R1 expression.17
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Intermediate levels of IL-1R1 mRNA were detected 
in the three astrocyte lines and IL-1R1 mRNA was not 
detected in the two microglial cell lines. In vivo microglial 
and astrocyte expression of IL-1R1 was not found in many 
studies in the normal adult brain by in situ hybridization or 
by immunohistochemistry.14–16 After brain injury, however, 
IL-1R1 expression in astrocytes and microglia near the site 
of injury has been reported.18 In vitro, IL-1 can directly alter 
the phenotype of astrocytes19 and induce the expression of 
proMMP9,20 S100B,9 and EP3 receptors on astrocytes;21 
direct action of IL-1 on primary (postnatal) mouse   microglial 
c  ulture has been shown to induce the e  xpression of 
I  L-17.7 Thus, IL-1R1 may be expressed in activated   astrocytes 
and microglia or it may be expressed in these cell types dur-
ing development. The astrocyte and microglial cell lines used 
in the present study may represent only part of the in vivo 
phenotype spectrum of these cell types.
The three astrocyte cell lines used in the present study 
represent the type 1 (C8-D1A), type 2 (C8-S), and type 
3 (C8-D30) astrocytes. In culture, C8-D1A and C8-S 
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a cell adhesion molecule, VCAM-1, in C8-D30 and C8-D1A 
cells. Interestingly, the highest induction of VCAM is seen in 
the C8-D1A cells (VCAM-1/G3PDH = 0.0018 ± 0.0002), not 
C8-D30 cells (VCAM-1/G3PDH = 9.8 × 10-4 ± 6 × 10-4). It is 
possible, the type 1 astrocytes (C8-D1A) are more associated 
with the brain blood vessels in vivo than the type 3 astrocytes 
(C8-D30) and, therefore, are more involved in vascular 
l  eukocyte infiltration that requires the presence of cell adhe-
sion molecules at the blood brain barrier.25 It is striking that 
no VCAM-1 expression was induced in the C8-S cells. This 
is consistent with the notion that these type 2 astrocytes may 
be similar to the fibrous astrocytes in vivo, which are mainly 
present in the white matter as structural glial cells.26
The broadest and the strongest induction of gene 
expression by IL-1β in the present study was found in the 
endothelial cell line. IL-1β induced the expression of both 
chemokines (MCP-1 and CXCL-1), both adhesion molecules 
(ICAM-1 and VCAM-1), a cytokine (IL-6), and an inflam-
matory mediator (COX-2) expression. The IL-1β-induced 
expression levels of MCP-1, CXCL-1, and VCAM-1 in 
the endothelial cells were all significantly higher than their 
counterparts found in any of the three astrocytes. Thus, IL-1β 
acting directly on brain endothelial cells may be the dominant 
action during neuroinflammation. This is consistent with the 
observation that direct injection of IL-1β into the cerebral 
ventricles induces significant endothelial expression of a 
large number of inflammation related genes.8 In addition, 
the induction of COX-2 and IL-6 by IL-1β is only observed 
in the brain endothelial cells, not in the astrocytes. Thus, 
astrocytes may contribute to a smaller set of gene expression 
during IL-1β-induced neuroinflammation.
The two microglial cell lines tested did not respond to 
IL-1β stimulation, consistent with the fact that IL-1R1 could 
not be detected on these cells in the present study. Because 
previous studies showed that IL-1 may exert powerful 
effects on cells carrying very little IL-1R1,13 we stimulated 
these microglial cells with IL-1β in case our method was 
not sensitive enough to detect minute amounts of IL-1R1. 
IL-1β stimulation did not induce mRNA expression in any of 
the genes tested. Interestingly, in EOC2 cells, TNFα, IL-1β, 
MCP-1, and iNOS are constitutively expressed, whereas in 
EOC20 cells, only TNFα, IL-1β, and MCP-1 are constitu-
tively expressed. Therefore, EOC2 and EOC20 may represent 
microglial cells that are at different activation states.   Previous 
studies showed that microglia is a major cellular source of 
the proinflammatory cytokines IL-127–29 and TNFα30,31 in 
the CNS. The present results confirm this notion, but they 
also show that microglia may not be the responder cells to 
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have small somata while C8-D30 has a large somata and 
no processes. C8-D1A contains multiple short processes 
while C8-S has only two processes with one of them being 
very thin and long. These cells may resemble d  ifferent 
subtypes of astrocytes in vivo. Thus far, C8-D1A has 
been used most frequently in the analysis of astrocyte 
functions in vitro.22,23 It is interesting to note that C8-S, 
which has the morphology of structural fibrous astrocytes 
in vivo, expresses the least amount of IL-1R1 (IL-1R1/
G3PDH = 4.1 × 10-5 ± 2 × 10-5), whereas C8-D30, which 
has morphology resembling a phagocytic or reactive 
a  strocyte in tissue,24 expresses the highest amount of 
IL-1R1 (IL-1R1/G3PDH = 2.8 × 10-4 ± 8.4 × 10-5).
IL-1R1 is not detected in the two microglial cell lines. 
These cells may resemble themicroglia in vivo that have not 
been activated to the state of IL-1R1 expression.
In the three astrocytes, IL-1β induced significant expres-
sion of MCP-1, a monocyte chemokine, and CXCL-1, a 
neutrophil chemokine, with the strongest induction seen in 
the C8-D30 cells (MCP-1/G3PDH = 0.069 ± 0.006; CXCL-1/
G3PDH = 0.046 ± 0.004). These results suggest that the 
a  ctivated astrocytes may contribute to chemotaxis when they 
are stimulated by IL-1β. IL-1β also induced the expression of Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Cell type-specific actions of IL-1
IL-1. This is different from some peripheral monocytes in 
which IL-1 induces its own expression.32 Therefore, unless 
microglia is activated to the state of an IL-1R1-expressing 
cell, it is not likely to trigger self-amplifying neuroinflam-
mation in the brain.
IL-1β-induced expression of MCP-1, CXCL-1, and 
VCAM-1 in the astrocytes is blocked by the inhibitor of 
NF-κB, not the inhibitors of ERK, JNK, and p38 MAPK, 
demonstrating that IL-1β induces the expression of these 
genes exclusively via the NF-κB pathway in astrocytes. 
In the brain endothelial cells, IL-1β-induced expression 
of MCP-1, CXCL-1, VCAM-1, ICAM-1, and IL-6 was 
also blocked by the inhibitor of NF-κB, not the inhibitors 
of other signal transduction pathways. On the other hand, 
IL-1β-induced expression of COX-2 is not blocked by the 
inhibitor of NF-κB, but by the inhibitor of p38 MAPK 
in the brain endothelial cells. This is surprising because 
IL-1β-induced COX-2 expression has been shown to be 
mediated by ERK, JNK, p38, and NF-κB in fibroblasts,33 
and by NF-κB in epithelial cells34 in the literature. 
Therefore signaling pathways that mediate IL-1-induced 
COX-2 expression and the expression of other inflamma-
tory genes may be segregated as a unique feature of brain 
endothelial cells. This has important implications in how 
IL-1-induced neuroinflammation and neural signaling may 
be separately regulated. Previously, studies have shown that 
in vivo COX-2 expression in brain endothelial cells is an 
intermediate step in transmitting peripheral IL-1 signals 
to the brain,5,35 and brain endothelial NF-κB activation is 
associated with CNS IL-1-mediated neuroinflammation.8 
Interestingly, both CNS and peripheral IL-1 can induce 
brain endothelial COX-2 e  xpression, but only CNS IL-1 
can induce neuroinflammation that is characterized by 
l  eukocyte infiltration into the brain.8 It is intriguing to specu-
late that IL-1-induced neuroinflammation, via endothelial 
NF-κB, and IL-1-induced neural signaling, via endothelial 
COX-2, could be separated due to the fact that the different 
e  ndothelial signal transduction pathways are operative for 
these two different functions.
The distinct cell type-specific induction patterns caused 
by IL-1β stimulation occurred at both mRNA and protein 
levels. Results presented in Figure 7 show IL-1β-induced 
protein expression of MCP-1, VCAM-1, IL-6, and COX-2 in 
different cell lines largely resembles the patterns found for 
the expression of mRNAs of these molecules. For example, 
VCAM-1 mRNA was induced by IL-1β in both C8-D1A 
and C8-D30 cells, but not in C8-S cells (Figure 5). 
S  imilarly, VCAM-1 protein was induced in the C8-D1A and 
C8-D30 cells, but not in C8-S cells (Figure 7). In addition, 
COX-2 protein was induced only in the brain endothelial 
cell line, not in the astrocyte cell lines. This result parallels 
the results of COX-2 mRNA induction patterns described 
in   Figures 2 and 3. Among the three astrocyte cell lines, 
C8-S was the least responsive to IL-1β stimulation in terms 
of induction of MCP-1, VCAM-1, and IL-6 at both mRNA 
and protein levels. The only disparate induction patterns 
between mRNA and protein levels were found in IL-6 
e  xpression levels in C8-D30 cells. In these cells, IL-1β did not 
induce increased IL-6 mRNA expression (data not shown), 
but induced   significant IL-6 protein expression (  Figure 7). 
It is known that in certain cell types, IL-1 can induce 
increased production of IL-6 without increased t  ranscription 
of IL-6 mRNA via a mechanism of mRNA stabilization.36 
It is possible, that in C8-D30 cells, IL-1β induces increased 
IL-6 protein levels via this mechanism.
In summary, IL-1 acting directly on astrocytes, microglia, 
and endothelial cells induces cell type-specific responses. 
Microglial cells tested in the present study constitutively 
expressed IL-1, but did not respond to IL-1. The astrocyte 
responses to IL-1 can be differentiated by the subtype of 
astrocytes tested, with the reactive astrocytes exhibiting 
the strongest induction of neuroinflammatory genes and the 
structural astrocytes the weakest induction of these genes. 
The strongest responders to IL-1 were the brain endothelial 
cells, which used NF-κB-mediated pathways to express 
genes related to leukocyte infiltration, but p38 MAPK to 
express COX-2.
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